Replies to post #256557 on Innovation Pharmaceuticals Inc (IPIX)

[loanranger]

Try p. 12:
https://www.sec.gov/Archives/edgar/data/1355250/000147793218004457/ipix_10k.htm

I would've posted what I think it says but patents are tricky...witness the recent PR.

I did notice something that some might find interesting, though:
Under the Compounds For Use In Treatment Of Mucositis patent it says this:
"Methods of treating mucositis with Brilacidin and related compounds, and compositions of Brilacidin and palifermin"

https://medlineplus.gov/druginfo/meds/a605017.html

[keltoi]

December 12, 2017 (GLOBE NEWSWIRE) Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today that the European Patent Office has granted a European patent for Brilacidin, the Company’s first-in-class defensin-mimetic, in the prevention and control of Oral Mucositis (OM). Brilacidin-OM is being developed under an FDA Fast Track designation for this indication.

The European patent supplements other Brilacidin-OM patents that have been granted in the United States, Asia (Japan, Taiwan, China), Oceania (Australia) and South Africa. All currently issued patents have an expiration date of 2032. Additional Brilacidin-OM patent applications are pending in other key markets including Russia and South Korea.


NOTE:EXP.DATE 2032

LR and others "conveniently" ignore that.